Kenneth E. Freeman, MBA, MPA, PhD
Vice President
kenneth.freeman@newhillmgt.com
Ken is Director of Research at New Hill and oversees the analytical process. He cofounded and served as Vice Chairman of the Supervisory Board of NADAG, a biotech company in Germany (MIT spinout). Ken was Senior Director Financial Operations and a Member of the Board of Directors of ThromboGenics Ltd. (spinout Katholieke Universiteit Leuven), a company in which East Hill was the institutional investor. He served as CFO and Vice President Corporate Development for Pepscan (spinout IDO-Lelystad). Ken was a Consultant at UCL Biomedica and has extensive experience as a consultant in a variety of technology oriented industries, was a member of the Board of Directors of the Irish Bio Industry Association, and served as a Senior Analyst at the US Congressional Office of Technology Assessment.
He has been a Case Writer for London Business School and INSEAD and designed and conducted Business Planning Workshops at Flanders Business School, been a Visiting Scholar at CIS, MIT, a Professor at the US Naval War College, an Associate Fellow at the Royal United Services for Defense Studies, London and has played an active role in fostering entrepreneurship in Europe.
Ken holds a BA, magna cum laude, in International Relations from Eisenhower College, an MBA from Harvard Business School, a two year MPA from the J.F. Kennedy School of Government, Harvard, and a Ph.D. from King's College, London.